Asset Details
Do you wish to reserve the book?
A competing risk model analysis of dexmedetomidine of in-hospital mortality in subarachnoid hemorrhage patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A competing risk model analysis of dexmedetomidine of in-hospital mortality in subarachnoid hemorrhage patients
Do you wish to request the book?
A competing risk model analysis of dexmedetomidine of in-hospital mortality in subarachnoid hemorrhage patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A competing risk model analysis of dexmedetomidine of in-hospital mortality in subarachnoid hemorrhage patients
2024
Overview
Subarachnoid hemorrhage (SAH) is a severe cerebrovascular disorder characterized by the sudden influx of blood into the subarachnoid space. The use of sedatives may be associated with the prognosis of SAH patients. We obtained SAH data from the MIMIC-IV database. The receiver operating characteristic curve, Delong test, and decision curve analysis were used to assess the predictive value of sedatives. Propensity score matching (PSM) method was applied to match samples at a 1:1 ratio. Logistic regression analysis, generalized linear regression analysis, and stratified analysis were used to investigate the association of the sedative with in-hospital mortality and length of hospital stay (LOS). Finally, a competing risk analysis was performed to evaluate the survival probability with two potential outcomes. Dexmedetomidine had a better prognosis value than Propofol and Midazolam. After PSM analysis, the Dexmedetomidine and the non-Dexmedetomidine groups had 248 samples each. The application of Dexmedetomidine reduced the risk of in-hospital mortality but might prolong the LOS. When considering in-hospital mortality as a competing risk factor for LOS, Dexmedetomidine was a protective factor for in-hospital mortality but had no significant relationship with LOS. In conclusion, treatment of Dexmedetomidine could reduce the risk of in-hospital mortality with satisfactory predictive efficiency.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
